|
1
|
Committee of Hepatology, Chinese Research
Hospital Association; Fatty Liver Expert Committee, Chinese Medical
Doctor Association; National Workshop on Fatty Liver and Alcoholic
Liver Disease, Chinese Society of Hepatology; National Workshop on
Liver and Metabolism, Chinese Society of Endocrinology, Chinese
Medical Association, . Expert recommendations on standardized
diagnosis and treatment for fatty liver disease in China (2019
revised edition). Zhonghua Gan Zang Bing Za Zhi. 27:748–753.
2019.(In Chinese). PubMed/NCBI
|
|
2
|
Yu Y, Cai J, She Z and Li H: Insights into
the epidemiology, pathogenesis, and therapeutics of nonalcoholic
fatty liver diseases. Adv Sci (Weinh). 6:18015852018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu XL, Cao HX and Fan JG: MicroRNAs as
biomarkers and regulators of nonalcoholic fatty liver disease. J
Dig Dis. 17:708–715. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Miyaaki H, Ichikawa T, Kamo Y, Taura N,
Honda T, Shibata H, Milazzo M, Fornari F, Gramantieri L, Bolondi L
and Nakao K: Significance of serum and hepatic microRNA-122 levels
in patients with non-alcoholic fatty liver disease. Liver Int.
34:e302–307. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yamada H, Suzuki K, Ichino N, Ando Y,
Sawada A, Osakabe K, Sugimoto K, Ohashi K, Teradaira R, Inoue T, et
al: Associations between circulating microRNAs (miR-21, miR-34a,
miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta.
424:99–103. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chai C, Rivkin M, Berkovits L, Simerzin A,
Zorde-Khvalevsky E, Rosenberg N, Klein S, Yaish D, Durst R,
Shpitzen S, et al: Metabolic circuit involving free fatty acids,
microRNA 122, and triglyceride synthesis in liver and muscle
tissues. Gastroenterology. 153:1404–1415. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yamada H, Ohashi K, Suzuki K, Munetsuna E,
Ando Y, Yamazaki M, Ishikawa H, Ichino N, Teradaira R and Hashimoto
S: Longitudinal study of circulating miR-122 in a rat model of
non-alcoholic fatty liver disease. Clin Chim Acta. 446:267–271.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Singh S, Osna NA and Kharbanda KK:
Treatment options for alcoholic and non-alcoholic fatty liver
disease: A review. World J Gastroenterol. 23:6549–6570. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Salomone F, Godos J and Zelber-Sagi S:
Natural antioxidants for non-alcoholic fatty liver disease:
Molecular targets and clinical perspectives. Liver Int. 36:5–20.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yao J, Zhi M, Gao X, Hu P, Li C and Yang
X: Effect and the probable mechanisms of silibinin in regulating
insulin resistance in the liver of rats with non-alcoholic fatty
liver. Braz J Med Biol Res. 46:270–277. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nair A, Morsy MA and Jacob S: Dose
translation between laboratory animals and human in preclinical and
clinical phases of drug development. Drug Dev Res. 79:373–382.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta DeltaC(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tilg H and Moschen AR: Evolution of
inflammation in nonalcoholic fatty liver disease: The multiple
parallel hits hypothesis. Hepatology. 52:1836–1846. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lindenmeyer CC and McCullough AJ: The
natural history of nonalcoholic fatty liver disease-an evolving
view. Clin Liver Dis. 22:11–21. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bouderba S, Sanchez-Martin C, Villanueva
GR, Detaille D and Koceir EA: Beneficial effects of silibinin
against the progression of metabolic syndrome, increased oxidative
stress, and liver steatosis in Psammomys obesus, a relevant animal
model of human obesity and diabetes. J Diabetes. 6:184–192. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vecchione G, Grasselli E, Voci A, Baldini
F, Grattagliano I, Wang DQ, Portincasa P and Vergani L: Silybin
counteracts lipid excess and oxidative stress in cultured steatotic
hepatic cells. World J Gastroenterol. 22:6016–6026. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Salamone F, Galvano F, Cappello F,
Mangiameli A, Barbagallo I and Li Volti G: Silibinin modulates
lipid homeostasis and inhibits nuclear factor kappa B activation in
experimental nonalcoholic steatohepatitis. Transl Res. 159:477–486.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cui CX, Deng JN, Yan L, Liu YY, Fan JY, Mu
HN, Sun HY, Wang YH and Han JY: Silibinin Capsules improves high
fat diet-induced nonalcoholic fatty liver disease in hamsters
through modifying hepatic de novo lipogenesis and fatty acid
oxidation. J Ethnopharmacol. 208:24–35. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Salomone F, Barbagallo I, Godos J, Lembo
V, Currenti W, Cinà D, Avola R, D'Orazio N, Morisco F, Galvano F
and Li Volti G: Silibinin restores NAD+ levels and
induces the SIRT1/AMPK pathway in non-alcoholic fatty liver.
Nutrients. 9:10862017. View Article : Google Scholar
|
|
20
|
Zhang Y, Hai J, Cao M, Zhang Y, Pei S,
Wang J and Zhang Q: Silibinin ameliorates steatosis and insulin
resistance during non-alcoholic fatty liver disease development
partly through targeting IRS-1/PI3K/Akt pathway. Int
Immunopharmacol. 17:714–720. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Feng YY, Xu XQ, Ji CB, Shi CM, Guo XR and
Fu JF: Aberrant hepatic microRNA expression in nonalcoholic fatty
liver disease. Cell Physiol Biochem. 34:1983–1997. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Calo N, Ramadori P, Sobolewski C, Romero
Y, Maeder C, Fournier M, Rantakari P, Zhang FP, Poutanen M, Dufour
JF, et al: Stress-activated miR-21/miR-21* in hepatocytes promotes
lipid and glucose metabolic disorders associated with high-fat diet
consumption. Gut. 65:1871–1881. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu CH, Ampuero J, Gil-Gomez A,
Montero-Vallejo R, Rojas A, Muñoz-Hernández R, Gallego-Durán R and
Romero-Gómez M: miRNAs in patients with non-alcoholic fatty liver
disease: A systematic review and meta-analysis. J Hepatol.
69:1335–1348. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Su D, Zhang R, Hou F, Chi J, Huang F, Yan
S, Liu L, Deng Y, Wei Z and Zhang M: Lychee pulp phenolics
ameliorate hepatic lipid accumulation by reducing miR-33 and
miR-122 expression in mice fed a high-fat diet. Food Funct.
8:808–815. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Naderi M, Pazouki A, Arefian E, Hashemi
SM, Jamshidi-Adegani F, Gholamalamdari O, Soudi S, Azadmanesh K,
Samiee SM, Merat S, et al: Two triacylglycerol pathway genes,
CTDNEP1 and LPIN1, are down-regulated by hsa-miR-122-5p in
hepatocytes. Arch Iran Med. 20:165–171. 2017.PubMed/NCBI
|
|
26
|
Khakinezhad Tehrani F, Ranji N, Kouhkan F
and Hosseinzadeh S: Apoptosis induction and proliferation
inhibition by silibinin encapsulated in nanoparticles in MIA PaCa-2
cancer cells and deregulation of some miRNAs. Iran J Basic Med Sci.
23:469–482. 2020.PubMed/NCBI
|
|
27
|
Zadeh MM, Motamed N, Ranji N, Majidi M and
Falahi F: Silibinin-induced apoptosis and downregulation of
microRNA-21 and microRNA-155 in MCF-7 human breast cancer cells. J
Breast Cancer. 19:45–52. 2016. View Article : Google Scholar : PubMed/NCBI
|
